NeuroMetrix Wins Electronics Retailer Association Award for Quell TV Advertising
September 16 2016 - 12:39PM
Business Wire
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that the
Company’s Quell® Wearable Pain Relief Technology™ has won the
Electronics Retailer Association Moxie Award for the Best Health
Show 2016. This Moxie award recognizes the year’s best direct
response television campaigns.
“We are proud that Quell advertising was recognized with the
prestigious Moxie award,” said Frank McGillin, Senior Vice
President and General Manager, Consumer. “Quell is a breakthrough
for the 100 million Americans suffering from chronic pain, and we
are pleased that our television campaign is effectively
communicating our message.”
About Quell Wearable Pain Relief Technology
Quell is FDA cleared and designed for the millions of people
suffering from chronic pain. The advanced wearable technology
delivers 100% drug free pain relief and is available without a
prescription. Quell can be used during the day while active, and at
night while sleeping. Quell gives users the option to start, stop,
and adjust therapy discreetly via their smartphone. It also
provides therapy utilization and advanced sleep tracking. Quell is
available at select healthcare professionals and retailers. To find
a Quell retailer, visit the Store Locator at QuellRelief.com.
About the Electronic Retailing Association
The Electronic Retailing Association (ERA) serves as the
exclusive trade association representing the $350 billion
direct-to-consumer marketplace. ERA membership spans the globe to
encompass all levels of direct marketers, from start-up companies
to global leaders that employ the power of direct response to
market across all platforms including television, digital media and
radio to achieve a consumer-direct, measurable and accountable
response. ERA can be visited on the Internet at
www.retailing.org.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven
healthcare company combining bioelectrical and digital medicine to
address chronic health conditions including chronic pain, sleep
disorders and diabetes. The company’s lead product is Quell®, an
over-the-counter wearable therapeutic device for chronic pain.
Quell is integrated into a digital health platform that helps
patients optimize their therapy and decrease the impact of chronic
pain on their quality of life. The company also markets DPNCheck®,
a rapid point-of-care test for diabetic neuropathy, which is the
most common long-term complication of Type 2 diabetes. The company
maintains an active research effort and has several pipeline
programs, including a therapeutic device for restless leg syndrome.
The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health
Sciences and Technology in 1996. For more information, please
visit www.NeuroMetrix.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160916005685/en/
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief
Financial Officerneurometrix.ir@neurometrix.com
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Mar 2024 to Apr 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Apr 2023 to Apr 2024